<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02661594</url>
  </required_header>
  <id_info>
    <org_study_id>DP10013</org_study_id>
    <nct_id>NCT02661594</nct_id>
  </id_info>
  <brief_title>Thorough QT Study of Intravenous Amisulpride</brief_title>
  <official_title>A Randomised, Double-blind, Four-period Crossover Study to Investigate the Effect of Intravenous APD421 on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acacia Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acacia Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomised, single-dose, crossover, placebo-controlled study to see if intravenous&#xD;
      amisulpride has any effect on the heart rhythm, in particular the QT interval, in healthy&#xD;
      adult volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1, randomised, single-dose, period-balanced, crossover, placebo- controlled study to&#xD;
      assess the effects of iv doses of amisulpride on the QT interval, corrected for heart rate by&#xD;
      Fridericia's formula (QTcF), in healthy male and female subjects of Caucasian and Japanese&#xD;
      ethnicity aged 20-45 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal Mean ΔΔQTcF</measure>
    <time_frame>24 hours</time_frame>
    <description>Maximal mean placebo-corrected change from baseline of QTcF (QT interval corrected for heart rate using the Fridericia formula) for single 5 mg and 40 mg iv doses of APD421. At each time point (2 mins, 8 mins, etc) the QTcF is compared to the pre-dosing &quot;baseline&quot; value, in order to calculate the change in QTcF (ΔQTcF). The value of ΔQTcF at each time point is then compared against the same time point for a placebo infusion, and the difference is calculated (ΔΔQTcF).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ABCD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A: APD421 5 mg followed by B: APD421 40 mg; C: Moxifloxacin 400 mg; D: Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BDAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B: APD421 40 mg; D: Placebo. A: APD421 5 mg C: Moxifloxacin 400 mg;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CADB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C: Moxifloxacin 400 mg A: APD421 5 mg D: Placebo B: APD421 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DCBA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>D: Placebo C: Moxifloxacin 400 mg B: APD421 40 mg A: APD421 5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APD421 5 mg</intervention_name>
    <description>Therapeutic dose of amisulpride</description>
    <arm_group_label>ABCD</arm_group_label>
    <arm_group_label>BDAC</arm_group_label>
    <arm_group_label>CADB</arm_group_label>
    <arm_group_label>DCBA</arm_group_label>
    <other_name>Amisulpride 5mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APD421 40 mg</intervention_name>
    <description>Supra-therapeutic dose of amisulpride</description>
    <arm_group_label>ABCD</arm_group_label>
    <arm_group_label>BDAC</arm_group_label>
    <arm_group_label>CADB</arm_group_label>
    <arm_group_label>DCBA</arm_group_label>
    <other_name>Amisulpride 40mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Positive control for assay sensitivity</description>
    <arm_group_label>ABCD</arm_group_label>
    <arm_group_label>BDAC</arm_group_label>
    <arm_group_label>CADB</arm_group_label>
    <arm_group_label>DCBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator to establish baseline for calculating change in QTcF</description>
    <arm_group_label>ABCD</arm_group_label>
    <arm_group_label>BDAC</arm_group_label>
    <arm_group_label>CADB</arm_group_label>
    <arm_group_label>DCBA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or female subjects aged between 20 and 45 years (inclusive) at screening.&#xD;
&#xD;
          2. Signed informed consent in the local language prior to any study-mandated procedure.&#xD;
&#xD;
          3. Japanese subjects defined as a person carrying a Japanese passport, who is a&#xD;
             descendant of four Japanese grandparents and has not been outside Japan for more than&#xD;
             five years prior to screening.&#xD;
&#xD;
          4. The Caucasian subjects should be distinguished especially by very light to brown skin&#xD;
             pigmentation and straight to wavy or curly hair, and should be indigenous to Europe,&#xD;
             northern Africa, western Asia, and India. Therefore, the study may as well include&#xD;
             Caucasian subjects from North America, Australia and South Africa&#xD;
&#xD;
          5. No clinically significant findings on the physical examination at screening and at&#xD;
             admission on Day -2.&#xD;
&#xD;
          6. Body mass index (BMI) between 18 and 25 kg/m2 (inclusive) at screening and at&#xD;
             admission on Day -2, body weight at least 48 kg.&#xD;
&#xD;
          7. Systolic blood pressure (SBP) 90-145 mmHg, diastolic blood pressure (DBP) 40-90 mmHg,&#xD;
             and heart rate (HR) 40-90 bpm (all inclusive), measured on the left arm, after 10&#xD;
             minutes in the supine position at screening and at admission on Day -2.&#xD;
&#xD;
          8. Triplicate 12-lead ECG without clinically relevant abnormalities measured after ten&#xD;
             minutes in the supine position at screening and on admission on Day -2.&#xD;
&#xD;
          9. 24-hour 12-lead Holter ECG or an equivalent assessment and/or submaximal exercise test&#xD;
             without clinically relevant abnormalities measured at screening.&#xD;
&#xD;
         10. Haematology, biochemistry and urinalysis test results not deviating from the normal&#xD;
             range to a clinically relevant extent at screening and at admission.&#xD;
&#xD;
         11. Subjects must agree to use acceptable methods of contraception:&#xD;
&#xD;
             Male subjects&#xD;
&#xD;
             Male subjects must use medically acceptable methods of contraception if their female&#xD;
             partner(s) is (are) pregnant or lactating from the time of the first administration of&#xD;
             treatment or study medication until three months following administration of the last&#xD;
             treatment or dose of study medication. Acceptable methods include:&#xD;
&#xD;
               -  Condom used with spermicidal foam/gel/film/cream/suppository&#xD;
&#xD;
               -  If the subject has undergone surgical sterilisation (vasectomy with documentation&#xD;
                  of azoospermia) a condom with spermicidal foam/gel/film/cream/suppository must be&#xD;
                  used.&#xD;
&#xD;
             Use acceptable methods of contraception if the male subject's partner could become&#xD;
             pregnant from the time of the first administration of treatment or study medication&#xD;
             until three months following administration of the last treatment or dose of study&#xD;
             medication. The acceptable methods of contraception are as follows:&#xD;
&#xD;
               -  Condom and occlusive cap (diaphragm or cervical/vault caps) with spermicidal&#xD;
                  foam/gel/film/cream/suppository.&#xD;
&#xD;
               -  Surgical sterilisation (vasectomy with documentation of azoospermia) and a&#xD;
                  barrier method (condom or occlusive cap [diaphragm or cervical/vault caps] used&#xD;
                  with spermicidal foam/gel/film/cream/suppository).&#xD;
&#xD;
               -  The female partner uses oral contraceptives (combination oestrogen/progesterone&#xD;
                  pills), injectable progesterone or subdermal implants and a barrier method&#xD;
                  (condom or occlusive cap [diaphragm or cervical/vault caps] used with spermicidal&#xD;
                  foam/gel/film/cream/suppository).&#xD;
&#xD;
               -  The female partner uses medically prescribed topically-applied transdermal&#xD;
                  contraceptive patch and a barrier method (condom or occlusive cap [diaphragm or&#xD;
                  cervical/vault caps] used with spermicidal foam/gel/film/cream/suppository).&#xD;
&#xD;
               -  The female partner has undergone documented tubal ligation (female&#xD;
                  sterilisation). In addition, a barrier method (condom or occlusive cap [diaphragm&#xD;
                  or cervical/vault caps] used with spermicidal foam/gel/film/cream/suppository)&#xD;
                  must be used.&#xD;
&#xD;
               -  The female partner has undergone documented placement of an intrauterine device&#xD;
                  (IUD) or intrauterine system (IUS) and the use of a barrier method (condom or&#xD;
                  occlusive cap [diaphragm or cervical/vault caps] used with spermicidal&#xD;
                  foam/gel/film/cream/suppository).&#xD;
&#xD;
               -  True abstinence: When this is in line with the preferred and usual lifestyle of&#xD;
                  the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal,&#xD;
                  post-ovulation methods) and withdrawal are not acceptable methods of&#xD;
                  contraception.&#xD;
&#xD;
             Female subjects&#xD;
&#xD;
             Female subjects of childbearing potential must use medically acceptable methods of&#xD;
             contraception from the time of the first administration of treatment or study&#xD;
             medication until three months following administration of the last treatment or dose&#xD;
             of study medication. Acceptable methods include:&#xD;
&#xD;
               -  A documented placement of an IUD or IUS and the use of a barrier method (condom&#xD;
                  or occlusive cap [diaphragm or cervical/vault caps) used with spermicidal&#xD;
                  foam/gel/film/cream/suppository]).&#xD;
&#xD;
               -  Documented tubal ligation (female sterilisation). In addition, a barrier method&#xD;
                  (condom or occlusive cap [diaphragm or cervical/vault caps] used with spermicidal&#xD;
                  foam/gel/film/cream/suppository) should also be used.&#xD;
&#xD;
               -  Double barrier method: Condom and occlusive cap (diaphragm or cervical/vault&#xD;
                  caps) with spermicidal foam/gel/film/cream/suppository.&#xD;
&#xD;
               -  True abstinence: When this is in line with the preferred and usual lifestyle of&#xD;
                  the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal,&#xD;
                  post-ovulation methods) are not acceptable methods of contraception.&#xD;
&#xD;
         12. Ability to communicate well with the Investigator in the local language, and to&#xD;
             understand and comply with the requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant and/or breastfeeding.&#xD;
&#xD;
          2. Received amisulpride for any indication within the last 2 weeks.&#xD;
&#xD;
          3. Allergy to amisulpride or any of the excipients of APD421.&#xD;
&#xD;
          4. History of vestibular disorder or history of dizziness.&#xD;
&#xD;
          5. Received anti-emetic therapy including corticosteroids within the last 2 weeks.&#xD;
&#xD;
          6. History or clinical evidence of any disease and/or existence of any surgical or&#xD;
             medical condition which might interfere with the absorption, distribution, metabolism&#xD;
             or excretion of the study drug (appendectomy and herniotomy allowed, cholecystectomy&#xD;
             not allowed).&#xD;
&#xD;
          7. History of epilepsy.&#xD;
&#xD;
          8. History of clinically significant syncope.&#xD;
&#xD;
          9. Family history of sudden death.&#xD;
&#xD;
         10. Family history of premature cardiovascular death.&#xD;
&#xD;
         11. Clinically significant history or family history of congenital long QT syndrome (e.g.&#xD;
             Romano-Ward syndrome, Jervell and Lange-Nielson syndrome) or Brugada's syndrome.&#xD;
&#xD;
         12. History of clinically significant arrhythmias and ischemic heart disease (especially&#xD;
             ventricular arrhythmias, atrial fibrillation (AF), recent conversion from AF or&#xD;
             coronary spasm).&#xD;
&#xD;
         13. Conditions predisposing the volunteer to electrolyte imbalances (e.g. altered&#xD;
             nutritional states, chronic vomiting, anorexia nervosa, bulimia nervosa).&#xD;
&#xD;
         14. ECG abnormalities in the standard 12-lead ECG (at screening and Day -2) and 24-hour&#xD;
             12-lead Holter ECG or an equivalent assessment and/or submaximal exercise test (at&#xD;
             screening) which in the opinion of the Investigator will interfere with the ECG&#xD;
             analysis.&#xD;
&#xD;
         15. Any clinically important abnormalities in rhythm, conduction or morphology of resting&#xD;
             ECG that may interfere with the interpretation of QTc interval changes. This includes&#xD;
             subjects with any of the following (at screening and Day -2 of Period 1):&#xD;
&#xD;
               -  Sinus node dysfunction.&#xD;
&#xD;
               -  Clinically significant PR (PQ) interval prolongation.&#xD;
&#xD;
               -  Intermittent second or third degree atrioventricular (AV) block.&#xD;
&#xD;
               -  Incomplete or complete bundle branch block.&#xD;
&#xD;
               -  Abnormal T-wave morphology.&#xD;
&#xD;
               -  Prolonged QT interval corrected with Bazett's formula (QTcB) &gt;450 ms or shortened&#xD;
                  QTcB &lt; 350 ms or family history of long QT syndrome.&#xD;
&#xD;
             Subject with borderline deviations from these criteria may be included if the&#xD;
             deviations do not pose a safety risk, and if agreed between the appointed Cardiologist&#xD;
             and the PI.&#xD;
&#xD;
         16. Signs and/or symptoms of a clinically relevant acute illness in the four-week period&#xD;
             prior to screening.&#xD;
&#xD;
         17. Veins unsuitable for intravenous puncture or cannulation on either arm (e.g. veins&#xD;
             that are difficult to locate, access or puncture, veins with a tendency to rupture&#xD;
             during or after puncture).&#xD;
&#xD;
         18. Known hypersensitivity to any medicines administered in the trial.&#xD;
&#xD;
         19. Treatment with any prescribed medication during the two weeks prior to first baseline&#xD;
             day.&#xD;
&#xD;
         20. Treatment with any over-the-counter (OTC) medications during the two weeks prior to&#xD;
             first baseline day.&#xD;
&#xD;
         21. Treatment with vitamins and/or minerals within 48 hours prior to the first baseline&#xD;
             day.&#xD;
&#xD;
         22. Treatment with another investigational drug within four weeks prior to dosing or&#xD;
             having participated in more than three investigational drug studies within one year&#xD;
             prior to dosing.&#xD;
&#xD;
         23. Confirmed positive results from urine drug screen (amphetamines, benzodiazepines,&#xD;
             cocaine, cannabinoids, opiates, barbiturates and methadone) or from the alcohol breath&#xD;
             test at screening and on Day -2.&#xD;
&#xD;
         24. History or clinical evidence of alcoholism or drug abuse. Alcohol abuse is defined as&#xD;
             regular weekly intake of more than 14 units (Using alcohol tracker&#xD;
             http://www.nhs.uk/Tools/Pages/NHSAlcoholtracker.aspx); drug abuse is defined as&#xD;
             compulsive, repetitive and/or chronic use of drugs or other substances with or without&#xD;
             problems related to their use and/or where stopping or a reduction in dose will lead&#xD;
             to withdrawal symptoms.&#xD;
&#xD;
         25. Excessive caffeine consumption, defined as ≥800 mg per day at screening (800 mg = 7&#xD;
             cups of coffee or 16 cups of tea).&#xD;
&#xD;
         26. Smoking within three months prior to screening or during the screening period.&#xD;
&#xD;
         27. Loss of 250 mL or more blood within three months prior to screening.&#xD;
&#xD;
         28. Positive results from the hepatitis serology, except for vaccinated subjects, at&#xD;
             screening.&#xD;
&#xD;
         29. Positive results from the HIV serology at screening.&#xD;
&#xD;
         30. Any circumstances or conditions, which, in the opinion of the Investigator, may affect&#xD;
             full participation in the study or compliance with the protocol.&#xD;
&#xD;
         31. Legal incapacity or limited legal capacity at screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriel Fox, MB BChir</last_name>
    <role>Study Director</role>
    <affiliation>Acacia Pharma Ltd</affiliation>
  </overall_official>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>January 14, 2016</study_first_submitted>
  <study_first_submitted_qc>January 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2016</study_first_posted>
  <results_first_submitted>July 7, 2017</results_first_submitted>
  <results_first_submitted_qc>July 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 30, 2017</results_first_posted>
  <last_update_submitted>November 27, 2018</last_update_submitted>
  <last_update_submitted_qc>November 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TQT</keyword>
  <keyword>amisulpride</keyword>
  <keyword>volunteer</keyword>
  <keyword>ECG</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Amisulpride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Forty (40) healthy, non-elderly, Caucasian and Japanese, male or female subjects were planned to enter the study. At least 10 subjects were to be Japanese and at least 40% of subjects for both races were to be male.</recruitment_details>
      <pre_assignment_details>Forty (40) healthy subjects entered the study. One subject voluntarily withdrew after Period 1 (moxifloxacin 400 mg) and another subject was withdrawn due to severe non-compliance with the protocol after receiving APD421 5 mg and 40 mg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ABCD</title>
          <description>A: APD421 5 mg followed by B: APD421 40 mg; C: Moxifloxacin 400 mg; D: Placebo</description>
        </group>
        <group group_id="P2">
          <title>BDAC</title>
          <description>B: APD421 40 mg; D: Placebo. A: APD421 5 mg C: Moxifloxacin 400 mg.</description>
        </group>
        <group group_id="P3">
          <title>CADB</title>
          <description>C: Moxifloxacin 400 mg A: APD421 5 mg D: Placebo B: APD421 40 mg</description>
        </group>
        <group group_id="P4">
          <title>DCBA</title>
          <description>D: Placebo C: Moxifloxacin 400 mg B: APD421 40 mg A: APD421 5 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ABCD</title>
          <description>A: APD421 5 mg followed by B: APD421 40 mg; C: Moxifloxacin 400 mg; D: Placebo.</description>
        </group>
        <group group_id="B2">
          <title>BDAC</title>
          <description>B: APD421 40 mg; D: Placebo. A: APD421 5 mg C: Moxifloxacin 400 mg.</description>
        </group>
        <group group_id="B3">
          <title>CADB</title>
          <description>C: Moxifloxacin 400 mg A: APD421 5 mg D: Placebo B: APD421 40 mg</description>
        </group>
        <group group_id="B4">
          <title>DCBA</title>
          <description>D: Placebo C: Moxifloxacin 400 mg B: APD421 40 mg A: APD421 5 mg</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.50" spread="4.22"/>
                    <measurement group_id="B2" value="26.82" spread="4.24"/>
                    <measurement group_id="B3" value="30.20" spread="8.07"/>
                    <measurement group_id="B4" value="27.44" spread="4.93"/>
                    <measurement group_id="B5" value="27.99" spread="5.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximal Mean ΔΔQTcF</title>
        <description>Maximal mean placebo-corrected change from baseline of QTcF (QT interval corrected for heart rate using the Fridericia formula) for single 5 mg and 40 mg iv doses of APD421. At each time point (2 mins, 8 mins, etc) the QTcF is compared to the pre-dosing &quot;baseline&quot; value, in order to calculate the change in QTcF (ΔQTcF). The value of ΔQTcF at each time point is then compared against the same time point for a placebo infusion, and the difference is calculated (ΔΔQTcF).</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5 mg IV APD421</title>
            <description>Single dose of 5 mg IV APD421 infused over 2 minutes</description>
          </group>
          <group group_id="O2">
            <title>40 mg IV APD421</title>
            <description>Single dose of 40 mg IV APD421 infused over 2 minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>IV placebo infused over 8 minutes</description>
          </group>
          <group group_id="O4">
            <title>Oral Moxifloxacin</title>
            <description>Single 400 mg oral dose of moxifloxacin</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal Mean ΔΔQTcF</title>
          <description>Maximal mean placebo-corrected change from baseline of QTcF (QT interval corrected for heart rate using the Fridericia formula) for single 5 mg and 40 mg iv doses of APD421. At each time point (2 mins, 8 mins, etc) the QTcF is compared to the pre-dosing &quot;baseline&quot; value, in order to calculate the change in QTcF (ΔQTcF). The value of ΔQTcF at each time point is then compared against the same time point for a placebo infusion, and the difference is calculated (ΔΔQTcF).</description>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="2.8" upper_limit="7.1"/>
                    <measurement group_id="O2" value="23.4" lower_limit="21.3" upper_limit="25.5"/>
                    <measurement group_id="O3" value="0.8" lower_limit="-1.4" upper_limit="2.9"/>
                    <measurement group_id="O4" value="12.3" lower_limit="10.1" upper_limit="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All AE's are to be reported within a timeframe of 24hours.</time_frame>
      <desc>All AE encountered during the study will be reported in detail in the source documents and noted in the AE section of the CRF from the date of subject consent, throughout the clinical conduct and up to the follow-up visit. for a period of 24hours</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Intravenous placebo: two infusions in parallel, one over 2 minutes, one over 8 minutes&#xD;
Placebo: Placebo comparator to establish baseline for calculating change in QTcF</description>
        </group>
        <group group_id="E2">
          <title>Amisulpride 5 mg</title>
          <description>Intravenous amisulpride 5 mg: infusion over 2 minutes; Intravenous placebo infused in parallel over 8 minutes&#xD;
Amisulpride 5 mg: Therapeutic dose of amisulpride</description>
        </group>
        <group group_id="E3">
          <title>Amisulpride 40 mg</title>
          <description>Intravenous amisulpride 40 mg: infusion over 8 minutes;&#xD;
Intravenous placebo infused in parallel over 2 minutes&#xD;
Amisulpride 40 mg: Supra-therapeutic dose of amisulpride</description>
        </group>
        <group group_id="E4">
          <title>Moxifloxacin</title>
          <description>Oral moxifloxacin 400 mg tablet administered once (not blinded)&#xD;
Moxifloxacin: Positive control for assay sensitivity</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Infusion Site Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion-related reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were no limitations and caveats with this study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Gabriel Fox</name_or_title>
      <organization>Acacia Pharma Ltd</organization>
      <phone>+44-(0)1223-919764</phone>
      <email>GabrielFox@acaciapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

